within Pharmacolibrary.Drugs.R_RespiratorySystem.R01A_DecongestantsAndOtherNasalPreparationsForTopical.R01AD02_Prednisolone;

model Prednisolone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.82,
    Cl = 2.0833333333333334e-06,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.061,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.025,
    Tlag = 600,
    Vdp = 0.084,
    k12 = 2.6666666666666664e-06,
    k21 = 2.6666666666666664e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Prednisolone</td></tr><tr><td>ATC code:</td><td>R01AD02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>61</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Prednisolone is a synthetic glucocorticoid, used for its anti-inflammatory and immunosuppressive effects in the treatment of a variety of conditions including allergies, asthma, autoimmune diseases, and certain types of cancer. It is an approved and commonly used medication in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (both sexes) following oral administration.</p><h4>References</h4><ol><li><p>de Truchis, C, et al., &amp; Boyer, O (2023). Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant. <i>British journal of clinical pharmacology</i> 89(5) 1532–1540. DOI:<a href=\"https://doi.org/10.1111/bcp.15610\">10.1111/bcp.15610</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36510685/\">https://pubmed.ncbi.nlm.nih.gov/36510685</a></p></li><li><p>Petersen, KB, et al., &amp; Schmiegelow, K (2003). Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. <i>Cancer chemotherapy and pharmacology</i> 51(6) 465–473. DOI:<a href=\"https://doi.org/10.1007/s00280-003-0602-3\">10.1007/s00280-003-0602-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12698270/\">https://pubmed.ncbi.nlm.nih.gov/12698270</a></p></li><li><p>Yoshida, K, et al., &amp; Chanu, P (2021). Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. <i>Journal of clinical pharmacology</i> 61(12) 1579–1591. DOI:<a href=\"https://doi.org/10.1002/jcph.1942\">10.1002/jcph.1942</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34273118/\">https://pubmed.ncbi.nlm.nih.gov/34273118</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R01AD02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Prednisolone;
